ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer
http://www.news4press.com/News/Rubrik.asp weiter lesen
http://www.news4press.com/News/Rubrik.asp weiter lesen
- Experienced Chief Medical Officer to advance ISA´s clinical pipeline
http://www.news4press.com/News/Rubrik.asp weiter lesen
-- AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019 -- Collaboration seeks to further leverage Moditope® platform
- Ceremony Conventio Medicinae held at University Medical Center
- First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer
- Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines
http://www.news4press.com/News/Rubrik.asp weiter lesen
- ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer - Optimum immunotherapy window in cancer identified
- Targeting and Activating Dendritic Cells is the Key to Success
- Seasoned executive brings over twenty years of commercial biotech and pharma experience
- Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and…
#8722 Leiden University Medical Center to study novel immunotherapeutic in HPV-positive head neck cancer patients